- Effectiveness and adherence of glecaprevir/pibrentasvir among Saudi population at a single tertiary hospital.
| Outcomes | n (%) | 95% CI |
|---|---|---|
| Overall SVR12 | 91 (98.9) | 94-99.8 |
| Virologic non-response | 1 (1.1) | 0.2-5.9 |
| Virologic failure | ||
| Yes | 0 (2.2) | - |
| No | 0 (94.6) | - |
| Missing data | 92 (3.3) | - |
| Appropriate duration of treatment (8 vs 12 weeks) | ||
| Yes | 23 (25.0) | 16.6-35.1 |
| No | 69 (75.0) | 65.2-83 |
| SVR12 achievement according to duration of treatment | ||
| 8 weeks | 23 (100) | 85-100 |
| 12 weeks | 68 (98.5) | 92.2-99.7 |
Values are presented as numbers and precentages and 95% confidence interval (CI). SVR12: sustained virologic response